Tirzepatide (Mounjaro / Zepbound) structure · GLP-1 / incretin

Tirzepatide (Mounjaro / Zepbound) 2D structure

Role: Drug
Family: GLP-1 / incretin agonist series
Mechanism class: GLP-1 / incretin
Parent scaffold: Semaglutide (Ozempic / Wegovy / Rybelsus)
Indication: T2D / obesity (dual GIP/GLP-1) · FDA/EMA

Structure source: Catalog seed (external identifier on file)
PubChem CID: 156588855
FDA / EMA: FDA/EMA
ClinicalTrials.gov: tirzepatide obesity
Regulatory status: Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov

How similarity is calculated

Hand-written analysis

Mechanism

티르제파타이드는 GIP·GLP-1 이중 작용 펩타이드입니다. 인크레틴 이중 자극이 체중·혈당 효과 크기를 키운다는 설명입니다. GI 부작용은 GLP-1 축과 겹칩니다.

Medicinal chemistry

단일 사슬에 두 수용체 활성을 넣은 아실화 펩타이드입니다. 세마글루타이드는 GLP-1 단일입니다.

Indication · context

2형 당뇨·비만 적응입니다. 인크레틴 맵에서 단일 vs 이중 vs 삼중(레타트루타이드)을 나눕니다.

SMILES

N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](C)C(=O)O

Related compounds

Comparisons · briefs

External IDs · BioMoa

PubChem CID 156588855 ChEMBL 검색 BioMoa · Mounjaro / Zepbound BioMoa bridge Open on the family map Flow Structure table Mechanism class

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Methodology

Tirzepatide (Mounjaro / Zepbound) structure · mechanism